Pyxis Oncology
Pyxis Oncology's revenue fell 14.2% to $14 million in fiscal 2025. Its operating margin was −609.2%, down from −554.1% a year earlier. Free cash flow was −$64 million. The diluted share count rose 6.3%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
Pyxis Oncology lost money in fiscal 2025: a net loss of $80 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 275 | 179 | 119 | 127 | 67 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | −82,196.0x | −8,946.0x | −927.7x |
| Current ratio | 14.9x | 5.9x | 4.8x | 7.5x | 3.4x |
| Quick ratio | 14.9x | 5.9x | 4.8x | 7.5x | 3.4x |
Cash flow
Projections
Project Pyxis Oncology's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Pyxis Oncology shares on the open market, and 1 insider sold $107,100, all of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jun 30, 2026 | Jakob DupontDirector | Sold plan | 35,000 | $3.06 | $107,100 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | — | — | −472.5% |
| Altman Z'' | −2.07 | −3.10 | −16.86 |
| Accruals ratio | −1.6% | −11.9% | −13.0% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | Fail |
| Revenue rose relative to assets | — | — | Fail |
| F-score | — | — | — |
Compare
Put Pyxis Oncology side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Pyxis Oncology | FY25 | −14.2% | −609.2% | −458.3% | — | — | — | |
| Opus Genetics | FY25 | 29.1% | −271.9% | — | — | — | 3 | Compare |
| Tonix Pharmaceuticals | FY25 | 29.9% | −959.0% | −787.5% | — | — | — | Compare |
| Evommune | FY25 | 85.7% | −623.6% | −589.8% | — | — | — | Compare |
| ProQR Therapeutics | FY25 | −15.9% | −273.1% | −338.3% | — | — | — | Compare |
6 years of figures
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | — | — | — | — | 16 | 14 |
| Revenue growth | — | — | — | — | — | −14.2% |
| Gross profit | — | — | — | — | 16 | 12 |
| Research and development | 9 | 51 | 86 | 50 | 59 | 74 |
| Operating income | −13 | −70 | −124 | −82 | −90 | −84 |
| Net income | −13 | −76 | −121 | −74 | −77 | −80 |
| Diluted EPS (US$) | −12.45 | −8.95 | −3.65 | −1.85 | −1.32 | −1.28 |
| Diluted shares (millions) | 1 | 8 | 33 | 40 | 58 | 62 |
| Cash flow | ||||||
| Cash from operations | −10 | −35 | −89 | −71 | −58 | −64 |
| Capital expenditure | 2 | 0 | 6 | 7 | 0 | 0 |
| Free cash flow | −12 | −36 | −96 | −77 | −58 | −64 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 6 | 16 | 17 | 13 | 12 |
| Balance sheet at fiscal year end | ||||||
| Cash and short-term investments | 8 | 275 | 179 | 119 | 127 | 67 |
| Debt incl. finance leases | — | — | — | — | — | — |
| Total assets | 10 | 280 | 211 | 174 | 157 | 92 |
| Total liabilities | 4 | 19 | 51 | 48 | 36 | 38 |
| Shareholders' equity | −16 | 261 | 161 | 126 | 121 | 53 |
| Margins and ratios | ||||||
| Gross margin | — | — | — | — | 97.1% | 82.8% |
| Operating margin | — | — | — | — | −554.1% | −609.2% |
| Net margin | — | — | — | — | −478.9% | −574.5% |
| Free cash flow margin | — | — | — | — | −358.7% | −458.3% |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | −472.5% |
| Return on capital | — | — | — | — | — | — |
| Return on equity | — | −61.9% | −57.2% | −51.5% | −62.8% | −91.4% |
| Return on assets | — | −52.4% | −49.1% | −38.3% | −46.7% | −64.0% |
| Net debt to EBITDA | — | — | — | — | — | — |